Description: Humalog KwikPen Mix 25 is a medication used to manage blood sugar levels in patients with diabetes mellitus. It is a combination insulin product containing two types of insulin: insulin lispro and insulin lispro protamine suspension. Humalog Mix 25 is designed to provide both rapid-acting and intermediate-acting insulin to help control postprandial (after-meal) and fasting blood glucose levels.

Active Substances:

1. Insulin Lispro: This component is a rapid-acting insulin analog that works quickly to lower blood sugar levels after meals. It mimics the natural insulin produced by the pancreas and is absorbed rapidly into the bloodstream.
2. Insulin Lispro Protamine Suspension: This component is an intermediate-acting insulin that is released gradually into the bloodstream, providing more prolonged blood sugar control between meals and overnight.

Uses: Humalog KwikPen Mix 25 is indicated for the treatment of diabetes mellitus in adults and children aged 3 years and older. It is used to improve glycemic control and prevent complications associated with high blood sugar levels, such as diabetic retinopathy, neuropathy, and nephropathy.

Mechanism of Action: Insulin lispro and insulin lispro protamine work together to regulate glucose metabolism in the body. Insulin lispro acts quickly to lower blood sugar levels by facilitating glucose uptake into cells, inhibiting glucose production in the liver, and promoting glycogen synthesis. Insulin lispro protamine provides a sustained insulin effect, helping to maintain stable blood sugar levels over an extended period.

Dosage and Administration: Humalog KwikPen Mix 25 is administered subcutaneously (under the skin) using the prefilled KwikPen device provided. The dosage and administration schedule may vary depending on factors such as the patient’s age, weight, blood glucose levels, and meal patterns. It is typically injected shortly before meals, with dosage adjustments made based on blood glucose monitoring and healthcare provider recommendations.

Precautions:

• Humalog KwikPen Mix 25 should not be used during episodes of hypoglycemia (low blood sugar) or if the patient is allergic to any of its components.
• It is important to follow proper injection technique and rotate injection sites to prevent lipodystrophy (changes in fat tissue) and ensure optimal insulin absorption.
• Close monitoring of blood glucose levels, particularly during periods of illness, stress, or changes in medication regimen, is essential to prevent hyperglycemia (high blood sugar) or hypoglycemia.

Side Effects: Common side effects of Humalog KwikPen Mix 25 may include:

• Hypoglycemia
• Injection site reactions (redness, swelling, or itching)
• Weight gain
• Hypokalemia (low potassium levels)
• Lipodystrophy at injection sites
• Allergic reactions (rare)

It is important to report any persistent or severe side effects to the healthcare provider promptly.

Storage: Humalog KwikPen Mix 25 should be stored in the refrigerator at a temperature of 2-8°C (36-46°F) until the expiration date indicated on the package. Once in use, the pen can be kept at room temperature (below 30°C or 86°F) for up to 28 days.

Disclaimer: Humalog KwikPen Mix 25 should only be used under the supervision of a qualified healthcare professional. It is important to discuss the risks and benefits of treatment with your healthcare provider before starting Humalog therapy. This medication may not be suitable for everyone, and individual responses may vary.